AUPHAurinia Pharmaceuticals Inc.
$16.86+46% 1Y
$16.86
$11.5552 weeks$18.62
Is the price fair?
What AUPH's price assumes
Aurinia Pharmaceuticals Inc. trades at 7.36× earnings against 19.8× for the median Biotechnology name, cheaper than its own group.
7.36
Trailing P/E · Biotechnology median 19.8 · cheaper than the typical name in its group
- Price / sales
- 7.27
Price / sales · as of 2026-Q2
- Price / book
- 3.68
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 3.68
- Healthcare median P/E503 names
- 27.9
- Biotechnology median P/E242 names
- 19.8
- Market capitalisation133.1 million shares, counted Aug 5, 2026
- $2.24B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.